Clinical research of dose - dense combinated pharmorubicin with paclitaxel in advanced breast cancer treatment / 重庆医科大学学报

ABSTRACT

Purpose;To observe curative effect and side reaction ,histopathology change of dose - dense combinated pharmorubicin with paclitaxel in advanced breast cancer treatment. Methods ;38 patients with advanced breast cancer diagnosed by pathology, which had e-valuation index, pharmorubicin 50mg/m2 ,d1 , intravenous injection,paclitaxel 175mg/m2,d2,intravenous injection,every 2 weeks as 1 course of treatment,after accepted 2 - 4 course of treatment,all patients were evaluated. Results: All patients were followed up,clinical complete remission( CR) 10. 5% , clinical partial remission 71. 1% , total effective rate 81. 6% . effective rate in patents of initial treatment was much higher than that in patients of retreatmen; effective rate in patents of III stage also was much higher than that in patients of IV stage; low leucocyte and Neutropenia appeared III ,IV side reaction,occupying respectively 63.2% and 71. 1% ;7.9% patients febricity owing to low leucocyte were cured by G - CSF and antibiotics,all patients successfully accomplish chemotherapy. Other side reaction,for instance thrombocytopenia.anaemia,nausea and vomiting etc,mostly displayed I , II toxic reaction,but they can be tolerated. After chemotherapy,cancer cells degeneration . cellular necrosis . retrogression and interstitial fibrosis .inflammatory cell infiltration are obviously changed. Conclusion: dose -dense chemotherapy combinated pharmorubicin with paclitaxel in advanced breast cancer treatment, remission rate was much higher and remission rate can be tolerated.